GSK reports before the bell today with Arexvy RSV vaccine rollout and Zantac litigation resolution both in focus for investors watching the pharma giant's commercial momentum. Continue ReadingShow ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results